Scholar Rock Holding (SRRK) Accounts Payables (2017 - 2026)
Scholar Rock Holding's quarterly Accounts Payables came in at $9.2 million in Q1 2026, up 107.75% year-on-year from $4.4 million in Q1 2025, and down 10.53% quarter-over-quarter from $10.3 million in Q4 2025.
Scholar Rock Holding has reported Accounts Payables for 10 years, with the latest figure at $9.2 million in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 107.75% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (up 107.75% YoY), and the FY2025 full-year result was $10.3 million, up 2.06% from the prior year.
- Accounts Payables for Q1 2026 stood at $9.2 million, down from $10.3 million in the prior quarter.
- The five-year high for Accounts Payables was $10.3 million in Q4 2025, with the low at $1.1 million in Q2 2025.
- Average Accounts Payables over 5 years is $4.5 million, with a median of $3.5 million recorded in 2023.
- Year-over-year, Accounts Payables surged 191.34% in 2024 and plunged 66.7% in 2025.
- Tracing SRRK's Accounts Payables over 5 years: stood at $4.0 million in 2022, then fell by 13.24% to $3.5 million in 2023, then surged by 191.34% to $10.1 million in 2024, then rose by 2.06% to $10.3 million in 2025, then slipped by 10.53% to $9.2 million in 2026.
- The last three Accounts Payables figures came in at $9.2 million (Q1 2026), $10.3 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 10.30 Mn |
| Sep 30, 2025 | 6.77 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 10.10 Mn |
| Sep 30, 2024 | 4.07 Mn |
| Jun 30, 2024 | 3.32 Mn |
| Mar 31, 2024 | 2.87 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 3.99 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 2.85 Mn |
| Mar 31, 2022 | 2.99 Mn |
| Dec 31, 2021 | 4.43 Mn |
| Sep 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 1.63 Mn |
| Mar 31, 2021 | 2.20 Mn |
| Dec 31, 2020 | 3.41 Mn |
| Sep 30, 2020 | 1.11 Mn |
| Jun 30, 2020 | 2.68 Mn |
| Mar 31, 2020 | 2.23 Mn |
| Dec 31, 2019 | 1.13 Mn |
| Sep 30, 2019 | 3.03 Mn |
| Jun 30, 2019 | 1.86 Mn |
| Mar 31, 2019 | 3.25 Mn |
| Dec 31, 2018 | 3.30 Mn |
| Sep 30, 2018 | 1.81 Mn |
| Jun 30, 2018 | 2.60 Mn |
| Dec 31, 2017 | 1.36 Mn |